Antibodies and venom peptides

new modalities for ion channels

Heike Wulff, Palle Christophersen, Paul Colussi, K. George Chandy, Vladimir Yarov-Yarovoy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. In parallel, after initial studies with polyclonal antibodies demonstrated the technical feasibility of inhibiting channel function with antibodies, multiple preclinical programmes are now using the full spectrum of available technologies to generate conventional monoclonal and engineered antibodies or nanobodies against extracellular loops of ion channels. After a summary of the current state of ion channel drug discovery, this Review discusses recent developments using the purinergic receptor channel P2X purinoceptor 7 (P2X7), the voltage-gated potassium channel KV1.3 and the voltage-gated sodium channel NaV1.7 as examples of targeting ion channels with biologics.

Original languageEnglish (US)
JournalNature Reviews Drug Discovery
DOIs
StatePublished - Jan 1 2019

Fingerprint

Venoms
Ion Channels
Peptides
Antibodies
Biological Products
NAV1.7 Voltage-Gated Sodium Channel
Purinergic P2X Receptors
Single-Domain Antibodies
Voltage-Gated Potassium Channels
Purinergic Receptors
Immunomodulation
Metabolic Diseases
Drug Discovery
Pharmaceutical Preparations
Cardiovascular Diseases
Pharmacokinetics
Monoclonal Antibodies
Technology
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Antibodies and venom peptides : new modalities for ion channels. / Wulff, Heike; Christophersen, Palle; Colussi, Paul; Chandy, K. George; Yarov-Yarovoy, Vladimir.

In: Nature Reviews Drug Discovery, 01.01.2019.

Research output: Contribution to journalReview article

@article{1f1074f577454ba3a5338b98fe3dc73f,
title = "Antibodies and venom peptides: new modalities for ion channels",
abstract = "Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. In parallel, after initial studies with polyclonal antibodies demonstrated the technical feasibility of inhibiting channel function with antibodies, multiple preclinical programmes are now using the full spectrum of available technologies to generate conventional monoclonal and engineered antibodies or nanobodies against extracellular loops of ion channels. After a summary of the current state of ion channel drug discovery, this Review discusses recent developments using the purinergic receptor channel P2X purinoceptor 7 (P2X7), the voltage-gated potassium channel KV1.3 and the voltage-gated sodium channel NaV1.7 as examples of targeting ion channels with biologics.",
author = "Heike Wulff and Palle Christophersen and Paul Colussi and Chandy, {K. George} and Vladimir Yarov-Yarovoy",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41573-019-0013-8",
language = "English (US)",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Antibodies and venom peptides

T2 - new modalities for ion channels

AU - Wulff, Heike

AU - Christophersen, Palle

AU - Colussi, Paul

AU - Chandy, K. George

AU - Yarov-Yarovoy, Vladimir

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. In parallel, after initial studies with polyclonal antibodies demonstrated the technical feasibility of inhibiting channel function with antibodies, multiple preclinical programmes are now using the full spectrum of available technologies to generate conventional monoclonal and engineered antibodies or nanobodies against extracellular loops of ion channels. After a summary of the current state of ion channel drug discovery, this Review discusses recent developments using the purinergic receptor channel P2X purinoceptor 7 (P2X7), the voltage-gated potassium channel KV1.3 and the voltage-gated sodium channel NaV1.7 as examples of targeting ion channels with biologics.

AB - Ion channels play fundamental roles in both excitable and non-excitable tissues and therefore constitute attractive drug targets for myriad neurological, cardiovascular and metabolic diseases as well as for cancer and immunomodulation. However, achieving selectivity for specific ion channel subtypes with small-molecule drugs has been challenging, and there currently is a growing trend to target ion channels with biologics. One approach is to improve the pharmacokinetics of existing or novel venom-derived peptides. In parallel, after initial studies with polyclonal antibodies demonstrated the technical feasibility of inhibiting channel function with antibodies, multiple preclinical programmes are now using the full spectrum of available technologies to generate conventional monoclonal and engineered antibodies or nanobodies against extracellular loops of ion channels. After a summary of the current state of ion channel drug discovery, this Review discusses recent developments using the purinergic receptor channel P2X purinoceptor 7 (P2X7), the voltage-gated potassium channel KV1.3 and the voltage-gated sodium channel NaV1.7 as examples of targeting ion channels with biologics.

UR - http://www.scopus.com/inward/record.url?scp=85061178869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061178869&partnerID=8YFLogxK

U2 - 10.1038/s41573-019-0013-8

DO - 10.1038/s41573-019-0013-8

M3 - Review article

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

ER -